Begoña Carazo Gallego

Begoña Carazo Gallego

Auto-generated profile, based on publicly available information

Begoña Carazo Gallego

Paediatric Infectious Diseases and Immunodeficiencies Málaga Regional University Hospital Málaga Spain

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2025 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
NMNatalia Mendoza-Palomar
Natalia Mendoza-Palomar
Silvia Simó NebotSilvia Simó Nebot
Silvia Simó Nebot
LRLaura Roig-Soria
Laura Roig-Soria
LGLaura Alonso García
Laura Alonso García
CAClara Izquierdo Anto
Clara Izquierdo Anto
PSPere Soler-Palacín
Pere Soler-Palacín
Background and Objectives: Isavuconazole (ISA) has been recently approved for the treatment of invasive aspergillosis and mucormycosis in patients aged >1 year. Prior to this approval, it was used in paediatric patients under compassionate use. The objective of this study is to describe the experience with ISA use in children. Patients and methods: A descriptive, retrospective, multicentre study conducted in nine Spanish hospitals, including patients aged ≤18 years who received ≥7 days of ISA between 2018 and 2023. Therapeutic drug monitoring (TDM) was performed with pre-dose [trough concentration (Ctrough)] levels measured according to local protocols. A therapeutic range of 2.5–5 mg/L was used for analysis. Results: A total of 107 patients (median age: 11 years, 56% male) were included. ISA was used as a treatment (95 patients), mostly as second-line therapy (64 patients, 67%), due to toxicity from previous antifungals (27 patients, 42%). Of 53 patients with proven/probable invasive fungal disease (IFD), 32 (60%) showed a favourable response and 21 (40%) died, 13 due to IFD. Twelve patients received ISA as prophylaxis and none developed breakthrough IFD. Overall, 27/107 (25%) patients experienced adverse effects, the most common being hepatotoxicity, with 10 requiring discontinuation. TDM was performed in 76/95 patients (80%), revealing 59% of Ctrough values outside the therapeutic range. Conclusions: ISA appears to be a safe and effective option for treating IFD in children, especially when first-line agents have failed or caused excessive toxicity. Although no correlation between Ctrough and clinical outcomes was observed, the significant proportion of patients with out-of-range Ctrough emphasizes the need for TDM in paediatrics.

18 August 2026 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
FCFuensanta Guerrero del Cueto
Fuensanta Guerrero del Cueto
LFLola Falcón-Neyra
Lola Falcón-Neyra
LCLeticia Martinez Campos
Leticia Martinez Campos
NFNadín Fernández-Vega
Nadín Fernández-Vega
BRBeatriz Ruiz-Saez
Beatriz Ruiz-Saez
ONOn Behalf Of The Gaip (Grupo Andaluz de Infectología e Inmunopatología Pediátrica) Network
On Behalf Of The Gaip (Grupo Andaluz de Infectología e Inmunopatología Pediátrica) Network
Background: Intracranial suppurative infections (epidural empyema, subdural empyema and brain abscess) are rare but severe pediatric conditions associated with diagnostic delay, neurological sequelae and heterogeneous management. Evidence guiding optimal antibiotic duration, route of administration and adjunctive corticosteroid use remains limited. Methods: We conducted a retrospective multicenter study, including children 2 years. Microbiological diagnosis was achieved in 72%; most isolates included Streptococcus species (42.7%). Empirical antibiotic regimens varied widely; vancomycin was used in 69.3% but frequently discontinued after culture results. The antibiotic route was switched to oral in 21 patients (28.8%), with no increased need for repeat surgical intervention or sequelae. Corticosteroids were used in 49.3% of cases. Sequelae occurred in 29.3%, more frequently in infants (<24 months: 45.5% vs. 22.6%, P = 0.048). Neurological deficits at presentation (odds ratio 8.22) and vomiting (odds ratio 3.55) were associated with sequelae. Mortality was 4.0%. Conclusions: Pediatric intracranial suppurative infections are associated with significant morbidity and marked variability in management across centers. Selected patients may safely transition to oral antibiotics after initial intravenous therapy, although prospective studies are needed. Standardized treatment protocols are required to optimize outcomes and reduce neurological sequelae.

29 October 2026 in Mycoses
Verified
Journal Article
Open access
NMNatalia Mendoza-Palomar
Natalia Mendoza-Palomar
CGCarlos Daniel Grasa
Carlos Daniel Grasa
BCBegoña Carazo‐Gallego
Begoña Carazo‐Gallego
ERElena María Rincón‐López
Elena María Rincón‐López
MPMaria Pinyol‐Sarrias
Maria Pinyol‐Sarrias
MMMaría Teresa Martín‐Gómez
María Teresa Martín‐Gómez
Introduction: Invasive aspergillosis (IA) represents one of the most frequent invasive fungal infections in paediatric patients with risk factors. An increase in cases of azole‐resistant IA has been reported in adult patients. The aim of this study is to present a series of 11 cases of paediatric patients with this pathology. Methods: A retrospective descriptive study including paediatric patients with probable or proven azole‐resistant IA treated between January 2019 and June 2024 in four tertiary hospitals in Spain. Results: Eleven cases are reported, all patients with risk factors for IA, mainly with haematopoietic stem cell transplantation (HCT) due to haematological malignancies and heart transplant in the early post‐transplant period. These patients represent 22% of all proven or probable paediatric IA cases ( n = 50) diagnosed in the study centres during the period. Five were previously receiving azole‐based antifungal prophylaxis. The most frequently isolated species was Aspergillus fumigatus . Despite receiving at least partially active antifungals plus adjunctive treatment therapy from diagnosis, attributable mortality was high (8/11 patients). Conclusion: Azole‐resistant IA should be suspected in paediatric patients with risk factors, especially if they show poor clinical course or have received azole prophylaxis. The performance of invasive tests, as well as species identification and resistance testing, is essential to optimise treatment. In breakthrough IA it should be considered empirical treatment with an antifungal from a different class than the one used for prophylaxis, alone or in combination.